Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Drugs Controller General of India (DCGI) approved India's first Quadri-valent Human Papillomavirus vaccine (qHPV) against cervical cancer.
The reforms include loosening restrictions on foreign institutional investors' (FPIs') ability to invest in the debt market and raising the automated route's external commercial borrowing (ECB) cap from USD 750 million or its equivalent to USD 1.5 billion.
EXAMIANS